These results could explain the significant clinical benefit obtained with platinum-pemetrexed and pembrolizumab combination as upfront treatment also in the subgroup of metastatic NSCLC patients with PD-L1 negative tumors [5]. The gene discussed is CD274; the disease is non-small cell lung carcinoma.